Alfred Newman, MD
Urology · Montgomery, ALNPI 1609864867
Payments from drug & device makers
Across 180 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$880
- Astellas Pharma US Inc$671
- Johnson & Johnson$449
- Antares Pharma, Inc.$376
- AbbVie$240
- Pfizer$197
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,24793%
- Education$3117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 26 | $880 |
| Astellas Pharma US Inc | 18 | $671 |
| Johnson & Johnson | 12 | $449 |
| Antares Pharma, Inc. | 22 | $376 |
| AbbVie(2 entities) | 11 | $240 |
| Pfizer | 7 | $197 |
| Myovant Sciences Inc. | 7 | $182 |
| Coloplast | 10 | $173 |
| Kowa Pharmaceuticals America, Inc. | 18 | $155 |
| Boston Scientific | 4 | $150 |
| Clarus Therapeutics Inc. | 7 | $124 |
| Accord Healthcare, Inc. | 1 | $91 |
| Urovant Sciences Inc | 2 | $90 |
| Myriad Genetic Laboratories, Inc. | 5 | $87 |
| Axonics, Inc. | 2 | $87 |
| Verity Pharmaceuticals Inc. | 4 | $85 |
| Healthtronics Stone Solutions, LLC | 1 | $83 |
| Endo Pharmaceuticals Inc. | 4 | $77 |
| ABC Home Medical Supply, Inc. | 2 | $45 |
| Tolmar, Inc. | 2 | $43 |
| Radius Health, Inc. | 2 | $34 |
| Zyla Life Sciences, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Urogen Pharma, Inc. | 1 | $25 |
| Rochester Medical Corporation | 1 | $22 |
| Blue Earth Diagnostics | 1 | $20 |
| Mckesson Patient Care Solutions Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Ambu Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$138
How this compares
$4,557 in reported general payments places this provider in the 50th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 47 | $805,223 |
| XtandiEnzalutamide | 52 | $733,321 |
| MyrbetriqMirabegron | 195 | $132,527 |
| GemtesaVibegron | 124 | $128,286 |
| OrgovyxRelugolix | 22 | $58,955 |
| JatenzoTestosterone Undecanoate | 17 | $17,701 |
| Tamsulosin Hcl | 790 | $13,703 |
| XyostedTestosterone Enanthate | 16 | $9,718 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 21 | $5,877 |
| Bicalutamide | 202 | $5,592 |
| Testosterone | 17 | $5,325 |
| NitrofurantoinNitrofurantoin Macrocrystal | 107 | $4,799 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 131 | $4,522 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $3,490 |
| Finasteride | 199 | $3,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $671 | $865,849247 claims |
| Johnson & JohnsonErleada | $449 | $805,22347 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $33 | $187,241146 claims |
| Clarus Therapeutics Inc.Jatenzo | $124 | $17,70117 claims |
| Antares Pharma, Inc.Xyosted | $376 | $9,71816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 179 urology providers in Alabama.
Other urology in Montgomery
- William SherrerMontgomery$11K
- Brian RichardsonMontgomery$10K
- James McMurrayHuntsville$4.7M
- Vincent BivinsHomewood$1.3M
- Charles WhiteMobile$735K
- Thomas ChiBirmingham$628K
- Charles BuggHomewood$544K
- Charles PeytonBirmingham$543K
- Brian ChristineHomewood$372K
- Austin LutzHomewood$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.